Somatic mutations and clonal hematopoiesis in aplastic anemia

New England Journal of Medicine

Volumn 373, Issue 1, 2015, Pages 35-47

  Yoshizato, T ^a   Dumitriu, B ^e   Hosokawa, K ^b,e   Makishima, H ^f   Yoshida, K ^a   Townsley, D ^e   Sato Otsubo, A ^a   Sato, Y ^a   Liu, D ^e   Suzuki, H ^a   Wu, C O ^e   Shiraishi, Y ^c   Clemente, M J ^f   Kataoka, K ^a   Shiozawa, Y ^a   Okuno, Y ^d   Chiba, K ^c   Tanaka, H ^c   Nagata, Y ^a   Katagiri, T ^b   Kon, A ^a   Sanada, M ^a   Scheinberg, P ^e   Miyano, S ^c   Maciejewski, J P ^f   Nakao, S ^b   Young, N S ^e   Ogawa, S ^a   more..

^a KYOTO UNIVERSITY   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA METHYLTRANSFERASE 3A; GENOMIC DNA;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AMPLICON; APLASTIC ANEMIA; ARTICLE; ASXL1 GENE; BCOR GENE; BCORL1 GENE; BLOOD SAMPLING; CHILD; CLONAL HEMATOPOIESIS; CONTROLLED STUDY; COPY NUMBER VARIATION; DNMT3A GENE; FEMALE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC PROCEDURES; GENETIC VARIABILITY; HEMATOPOIESIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KARYOTYPING; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUTATION RATE; MUTATIONAL ANALYSIS; MYELODYSPLASTIC SYNDROME; NEWBORN; NEXT GENERATION SEQUENCING; OVERALL SURVIVAL; PIGA GENE; PREVALENCE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; WHOLE EXOME SEQUENCING; YOUNG ADULT; AGE; BLOOD; CELL CLONE; DNA SEQUENCE; GENETICS; MORTALITY; MUTATION; RISK FACTOR;

AGE FACTORS; AGED; ANEMIA, APLASTIC; CLONE CELLS; FEMALE; HEMATOPOIESIS; HUMANS; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROMES; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SEQUENCE ANALYSIS, DNA;

EID: 84936160001     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1414799     Document Type: Article

References (41)

1. Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood 2006; 108: 2509-19.
2. Maciejewski JP, Selleri C, Sato T, Anderson S, Young NS. A severe and consistent deficit in marrow and circulating primitive hematopoietic cells (long-term culture-initiating cells) in acquired aplastic anemia. Blood 1996; 88: 1983-91.
3. Scheinberg P, Young NS. How I treat acquired aplastic anemia. Blood 2012; 120: 1185-96.
4. Scheinberg P, Nunez O, Weinstein B, et al. Horse versus rabbit anti thymocyte globulin in acquired aplastic anemia. N Engl J Med 2011; 365: 430-8.
5. Socié G, Rosenfeld S, Frickhofen N, Gluckman E, Tichelli A. Late clonal diseases of treated aplastic anemia. Semin Hematol 2000; 37: 91-101.
6. Mortazavi Y, Chopra R, Gordon-Smith EC, Rutherford TR. Clonal patterns of X-chromosome inactivation in female patients with aplastic anaemia studies using a novel reverse transcription polymerase chain reaction method. Eur J Haematol 2000; 64: 385-95.
7. Afable MG II, Wlodarski M, Makishima H, et al. SNP array-based karyotyping: differences and similarities between aplastic anemia and hypocellular myelodysplastic syndromes. Blood 2011; 117: 6876- 84.
8. Mikhailova N, Sessarego M, Fugazza G, et al. Cytogenetic abnormalities in patients with severe aplastic anemia. Haematologica 1996; 81: 418-22.
9. Katagiri T, Sato-Otsubo A, Kashiwase K, et al. Frequent loss of HLA alleles associated with copy number-neutral 6pLOH in acquired aplastic anemia. Blood 2011; 118: 6601-9.
10. Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011; 478: 64-9.
11. Nannya Y, Sanada M, Nakazaki K, et al. A robust algorithm for copy number detection using high-density oligonucleotide single nucleotide polymorphism genotyping arrays. Cancer Res 2005; 65: 6071-9.
12. Yamamoto G, Nannya Y, Kato M, et al. Highly sensitive method for genome wide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarrays. Am J Hum Genet 2007; 81: 114-26.
13. Ishwaran H, Kogalur UB, Blackstone EH, Lauer MS. Random survival forests. Ann Appl Stat 2008; 2: 841-60.
14. Simon N, Friedman J, Hastie T, Tibshirani R. Regularization paths for Cox's proportional hazards model via coordinate descent. J Stat Softw 2011; 39: 1-13.
15. Ley TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010; 363: 2424-33.
16. Gelsi-Boyer V, Trouplin V, Adélaïde J, et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 2009; 145: 788-800.
17. Damm F, Chesnais V, Nagata Y, et al. BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders. Blood 2013; 122: 3169-77.
18. Mortazavi Y, Merk B, McIntosh J, Marsh JC, Schrezenmeier H, Rutherford TR. The spectrum of PIG-A gene mutations in aplastic anemia/paroxysmal nocturnal hemoglobinuria (AA/PNH): A high incidence of multiple mutations and evidence of a mutational hot spot. Blood 2003; 101: 2833-41.
19. Nafa K, Bessler M, Castro-Malaspina H, Jhanwar S, Luzzatto L. The spectrum of somatic mutations in the PIG-A gene in paroxysmal nocturnal hemoglobinuria includes large deletions and small duplications. Blood Cells Mol Dis 1998; 24: 370- 84.
20. Haferlach T, Nagata Y, Grossmann V, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 2014; 28: 241-7.
21. Scheinberg P, Wu CO, Nunez O, Young NS. Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia. Br J Haematol 2009; 144: 206-16.
22. Scheinberg P, Cooper JN, Sloand EM, Wu CO, Calado RT, Young NS. Association of telomere length of peripheral blood leukocytes with hematopoietic relapse, malignant transformation, and survival in severe aplastic anemia. JAMA 2010; 304: 1358-64.
23. Welch JS, Ley TJ, Link DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 2012; 150: 264-78.
24. Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 2014; 371: 2488-98.
25. Genovese G, Khler AK, Handsaker RE, et al. Clonal hematopoiesis and bloodcancer risk inferred from blood DNA sequence. N Engl J Med 2014; 371: 2477-87.
26. Lane AA, Odejide O, Kopp N, et al. Low frequency clonal mutations recoverable by deep sequencing in patients with aplastic anemia. Leukemia 2013; 27: 968- 71.
27. Kulasekararaj AG, Jiang J, Smith AE, et al. Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome. Blood 2014; 124: 2698-704.
28. Heuser M, Schlarmann C, Dobbernack V, et al. Genetic characterization of acquired aplastic anemia by targeted sequencing. Haematologica 2014; 99(9): E165-e167.
29. Shlush LI, Zandi S, Mitchell A, et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 2014; 506: 328-33.
30. Yasuda T, Ueno T, Fukumura K, et al. Leukemic evolution of donor-derived cells harboring IDH2 and DNMT3A mutations after allogeneic stem cell transplantation. Leukemia 2014; 28: 426-8.
31. Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature 2001; 409: 860-921.
32. Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature 2013; 500: 415-21.
33. Jacobs KB, Yeager M, Zhou W, et al. Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet 2012; 44: 651-8.
34. Laurie CC, Laurie CA, Rice K, et al. Detectable clonal mosaicism from birth to old age and its relationship to cancer. Nat Genet 2012; 44: 642-50.
35. Xie M, Lu C, Wang J, et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med 2014; 20: 1472-8.
36. Busque L, Patel JP, Figueroa ME, et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet 2012; 44: 1179- 81.
37. Dumitriu B, Feng X, Townsley DM, et al. Telomere attrition and candidate gene mutations preceding monosomy 7 in aplastic anemia. Blood 2015; 125: 706-9.
38. Challen GA, Sun D, Jeong M, et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet 2012; 44: 23-31.
39. Abdel-Wahab O, Gao J, Adli M, et al. Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo. J Exp Med 2013; 210: 2641-59.
40. Murakami Y, Kosaka H, Maeda Y, et al. Inefficient response of T lymphocytes to glycosylphosphatidylinositol anchor-negative cells: Implications for paroxysmal nocturnal hemoglobinuria. Blood 2002; 100: 4116-22.
41. Gargiulo L, Papaioannou M, Sica M, et al. Glycosylphosphatidylinositol-specific, CD1d-restricted T cells in paroxysmal nocturnal hemoglobinuria. Blood 2013; 121: 2753-61.